{
    "title": "Looming obesity drug rivalry not a concern for Novo CEO",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-11430089/Looming-obesity-drug-rivalry-not-concern-Novo-CEO.html",
    "date": "2022-11-15",
    "keywords": [
        "drug",
        "obesity",
        "market",
        "jorgensen",
        "weightloss",
        "use",
        "grover",
        "maggie",
        "healthcare",
        "ingredient",
        "ozempic",
        "injection",
        "approval",
        "novo",
        "type",
        "cost",
        "price",
        "company",
        "demand",
        "inflation",
        "reduction",
        "act",
        "ira",
        "london",
        "entry",
        "drugmaker",
        "outlook",
        "month",
        "profit",
        "treatment",
        "family",
        "glp1",
        "hunger",
        "growth",
        "wegovy",
        "therapy",
        "turn",
        "interview",
        "leader",
        "area",
        "side",
        "heart",
        "disease",
        "control",
        "amp",
        "prevention",
        "antiobesity",
        "system",
        "employment",
        "need",
        "competition",
        "mounjaro",
        "fasttrack",
        "review",
        "data",
        "body",
        "amgen",
        "earlystage",
        "supply",
        "manufacturing",
        "capacity",
        "weight",
        "indication",
        "elon",
        "person",
        "twitter",
        "owner",
        "endorsement",
        "semaglutide",
        "offlabel",
        "defeat",
        "industry",
        "august",
        "precedent",
        "revenue",
        "note",
        "commentary",
        "fick",
        "editing",
        "alexander",
        "smith",
        "mark",
        "potter"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}